NCT00023894

Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Gynecologic Oncology Group · Network
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.

Detailed description

OBJECTIVES: * Determine the antitumor activity of flavopiridol in patients with recurrent or persistent endometrial carcinoma. * Determine the nature and degree of toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 10-24 months.

Conditions

• Endometrial Cancer

Interventions

Type	Name	Description
DRUG	alvocidib

Timeline

• Start date: 2001-07-01
• Completion: 2006-02-01
• First posted: 2003-01-27
• Last updated: 2013-06-24

Locations

54 sites across 5 countries: United States, Australia, Canada, Norway, United Kingdom